---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-202288"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:29:54.508047+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q2 net loss narrows to $21.1M; revenue jumps to $22.1M on GSK collaboration

## Summary
- Net loss of $21.1M vs $41.3M YoY; revenue of $22.1M from GSK/Takeda collaborations vs $0.4M in Q2 2022.
- Cash and equivalents $173.0M at June 30, 2023, up from $88.5M at Dec 2022; runway into 2025.
- Imminent CTA submission for WVE-006 (AATD RNA editing candidate); first-in-human study expected 2H 2023.
- DMD candidate WVE-N531 on track for potentially registrational Phase 2 dosing in 2H 2023; dystrophin data in 2024.
- Discontinued WVE-004 for C9-ALS/FTD, but biomarker data validated PN chemistry; HD candidate WVE-003 multi-dose dosing underway.

## SEC filing metadata
- accession: 0001193125-23-202288
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312523202288/0001193125-23-202288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312523202288/d584115d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-202288
- JSON: https://secwatch.observer/filing/0001193125-23-202288.json
- Plain text: https://secwatch.observer/filing/0001193125-23-202288.txt

## Key facts
- Earnings Releases
  Wave Life Sciences Ltd. reported the quarter ended June 30, 2023 results: revenue $22.1 million, net income a net loss of $21.1 million.
  - Period: the quarter ended June 30, 2023
  - Revenue: $22.1 million
  - Net income: a net loss of $21.1 million
  - Result: reported results
  source text: under the company’s collaboration with GSK, which became effective January 27, 2023. Revenue recognized under the GSK and Takeda collaborations in the second quarter of 2023 was $22.1 million. During the second quart
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523202288/0001193125-23-202288-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.